{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T10:13:53Z","timestamp":1789726433385,"version":"4.0.1"},"reference-count":30,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Therapeutic Advances in Drug Safety"],"published-print":{"date-parts":[[2020,1]]},"abstract":"<jats:p>With recent increase in the use of direct oral anticoagulants (DOACs), several new cases of adverse drug reactions (ADRs) have been identified in pharmacovigilance surveys. These ADRs can result in significant mortality and morbidity if not identified and treated promptly. It is important for physicians to recognize that immunologically mediated delayed hypersensitivity reactions, although rare in occurrence, can have significant impact on patient\u2019s quality of life. To the best of our knowledge, we report the first case of lichenoid eruption associated with apixaban. We further provide evidence of tolerance to rivaroxaban in the same patient.<\/jats:p>\n                  <jats:sec>\n                    <jats:title>Plain language summary<\/jats:title>\n                    <jats:p>Apixaban-induced lichenoid eruption Well documented case reports, although providing evidence of probable causal relationship between a drug and specific adverse drug reactions (ADRs), can increase awareness amongst clinicians treating patients with direct oral anticoagulants (DOACs), especially with its rapid utilization. Rare ADRs are difficult to detect as clinical trials of DOACs lacked enough patient sample, making post-marketing reporting of such events important so both patients and clinicians can be vigilant to help with prompt recognition of such symptoms. We report the first case of lichenoid eruption hypersensitivity reaction associated with apixaban in patient with tolerance to rivaroxaban.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/2042098620937884","type":"journal-article","created":{"date-parts":[[2020,8,18]],"date-time":"2020-08-18T01:37:18Z","timestamp":1597714638000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":8,"title":["A rare case report of apixaban-induced lichenoid eruption"],"prefix":"10.1177","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7257-3463","authenticated-orcid":false,"given":"Tanvi","family":"Patil","sequence":"first","affiliation":[{"name":"Department of Pharmacy, Salem Veterans Affair Medical Center (SVAMC), 1970 Roanoke Blvd, Salem, VA 24153, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suzanne","family":"Hanna","sequence":"additional","affiliation":[{"name":"Primary care\/ Dermatology, SVAMC, Salem, VA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wayne","family":"Torre","sequence":"additional","affiliation":[{"name":"Department of Pathology, SVAMC, Salem, VA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2020,8,17]]},"reference":[{"key":"bibr1-2042098620937884","doi-asserted-by":"publisher","DOI":"10.1016\/j.chest.2018.07.040"},{"key":"bibr2-2042098620937884","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-017-2296-1"},{"key":"bibr3-2042098620937884","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-07-590323"},{"key":"bibr4-2042098620937884","doi-asserted-by":"publisher","DOI":"10.1007\/s40629-015-0048-2"},{"key":"bibr5-2042098620937884","doi-asserted-by":"publisher","DOI":"10.2165\/00128071-200102020-00003"},{"key":"bibr6-2042098620937884","doi-asserted-by":"publisher","DOI":"10.1517\/14740338.1.3.287"},{"key":"bibr7-2042098620937884","doi-asserted-by":"publisher","DOI":"10.23822\/EurAnnACI.1764-1489.80"},{"key":"bibr8-2042098620937884","unstructured":"Eliquis [package insert]. Princeton, NJ: Bristol-Myers Squibb Company, 2012."},{"key":"bibr9-2042098620937884","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaip.2017.12.007"},{"key":"bibr10-2042098620937884","first-page":"213","volume":"16","author":"Veliyev V","year":"2016","journal-title":"Anatol J Cardiol"},{"key":"bibr11-2042098620937884","first-page":"38","volume":"51","author":"Cortellini G","year":"2019","journal-title":"Eur Ann Allergy Clin Immunol"},{"key":"bibr12-2042098620937884","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjmed.2014.05.013"},{"key":"bibr13-2042098620937884","doi-asserted-by":"publisher","DOI":"10.2174\/187152571201141201091848"},{"key":"bibr14-2042098620937884","doi-asserted-by":"publisher","DOI":"10.1177\/1203475417716364"},{"key":"bibr15-2042098620937884","first-page":"13","volume":"15","author":"Brauer J","year":"2009","journal-title":"Dermatol Online J"},{"key":"bibr16-2042098620937884","doi-asserted-by":"publisher","DOI":"10.1034\/j.1600-0536.2001.450601.x"},{"key":"bibr17-2042098620937884","doi-asserted-by":"publisher","DOI":"10.1016\/j.tox.2004.12.024"},{"key":"bibr18-2042098620937884","doi-asserted-by":"publisher","DOI":"10.2310\/7750.2008.08017"},{"key":"bibr19-2042098620937884","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-4632.2005.02266.x"},{"key":"bibr20-2042098620937884","doi-asserted-by":"publisher","DOI":"10.1016\/j.anai.2017.08.102"},{"key":"bibr21-2042098620937884","doi-asserted-by":"publisher","DOI":"10.14740\/jocmr3394w"},{"key":"bibr22-2042098620937884","doi-asserted-by":"publisher","DOI":"10.14740\/jmc3399"},{"key":"bibr23-2042098620937884","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2008.08529.x"},{"key":"bibr24-2042098620937884","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2008.09.032"},{"key":"bibr25-2042098620937884","first-page":"188","volume":"158","author":"Battistella M","year":"2008","journal-title":"Br J Dermatol"},{"key":"bibr26-2042098620937884","unstructured":"Food and Drug Administration. FDA adverse event reporting system public dashboard, https:\/\/fis.fda.gov\/sense\/app\/d10be6bb-494e-4cd2-82e4-0135608ddc13\/sheet\/59a37af8-d2bb-4dee-90bf-6620b1d5542f\/state\/analysis (accessed 14 January 2019)."},{"key":"bibr27-2042098620937884","unstructured":"eHeathMe: Real-World Drug Outcomes. Will you have rash with apixaban? https:\/\/www.ehealthme.com\/ds\/apixaban\/rash\/ (accessed 14 January 2019)."},{"key":"bibr28-2042098620937884","first-page":"575","volume-title":"Clinical aspects of immunology","author":"Coombs PRGP","year":"1968"},{"key":"bibr29-2042098620937884","doi-asserted-by":"publisher","DOI":"10.1186\/1756-0500-7-264"},{"key":"bibr30-2042098620937884","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.1981.154"}],"container-title":["Therapeutic Advances in Drug Safety"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/2042098620937884","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/2042098620937884","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/2042098620937884","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T23:39:34Z","timestamp":1777592374000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/2042098620937884"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1]]},"references-count":30,"alternative-id":["10.1177\/2042098620937884"],"URL":"https:\/\/doi.org\/10.1177\/2042098620937884","relation":{},"ISSN":["2042-0986","2042-0994"],"issn-type":[{"value":"2042-0986","type":"print"},{"value":"2042-0994","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,1]]},"article-number":"2042098620937884"}}